It's impossible to watch the evening news without seeing an update about the robustness of this year's influenza strains and the potential threat of the avian flu. Given the staggering mortality rate (about 52%) among human avian flu victims, I can't help but straighten up and listen to the reports as a knot develops in my stomach.
It's impossible to watch the evening news without seeing an update about the robustness of this year's influenza strains and the potential threat of the avian flu. Given the staggering mortality rate (about 52%) among human avian flu victims, I can't help but straighten up and listen to the reports as a knot develops in my stomach.
Kaylynn Chiarello-Ebner
Both infections pose legitimate public health threats; either could kill millions of people should a global pandemic arise. But, it's debatable whether this winter's impending threat is a true emergency or just a media circus.
Cynics in the crowd will note that many parties have inherent vested interests in public health emergencies. Everyone from politicians to investors in vaccine manufacturers have been accused of using public emergencies—or the perception of public emergencies—for personal gain.
It is nonetheless indisputable that most nations (the United States included) are vastly unprepared to protect their people against an outbreak of a highly contagious infectious disease such as the avian flu or countless other threats.
No matter which side you fall on, the flu vaccine dilemma highlights the vast gap between vaccine manufacturing capacity and public protection requirements. This season, the United States used all of the available doses (20 million) of influenza vaccine. To protect against a still conjectural avian influenza epidemic, we would need 300 million vaccine doses within the next 6 months, as CDC Director Julie Gerberding noted during the Nov. 20 edition of Meet the Press. To achieve this goal, almost every piece would need to fall into place perfectly, including developing new production methods. Fears about the flu have already spurred work in this area, but making information about new methods available to the public, and the profession, in a reliable, unbiased way is vital to the development process.
Kaylynn Chiarello-Ebner is the managing editor of Pharmaceutical Technology, kchiarello@advanstar.com.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.